India orders halt to ophthalmic production at Sun Pharma Assam plant after regulatory inspection finds quality lapses
Central and state drug regulators have ordered Sun Pharmaceutical Industries to stop manufacture, sale and distribution of ophthalmic products from its Assam sterile facility, following inspections that flagged shortcomings in quality management and a voluntary recall of hundreds of batches.